$1.56
-0.06(-3.70%)
Mkt Cap $7M
$1.52
$11.83
52-Week Range
At a Glance
AI-generatedTempest Therapeutics, a pre-revenue biotech, reported full fiscal 2025 operating losses and will require additional financing to advance its business objectives.
8-K
Tempest Therapeutics reported 2025 year-end financial results with reduced net loss of $26.3 million and $7.7 million cash, alongside positive TPST-2003 interim data and strategic CAR-T acquisition.$7M
Market Cap
—
Revenue
-$36M
Net Income
Employees24
Fundamentals
How The Business Makes Money
Tempest Therapeutics Inc., a clinical-stage oncology company, engages in developing small molecule therapeutics to treat cancer. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, and is currently in a Phase 1 trial in solid tumors; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial in solid tumors. It also develops TREX-1, a key cellular enzyme that regulates the innate immune response in tumors. The company was founded in 2011 and is headquartered in South San Francisco, California. Tempest Therapeutics Inc. was formerly a subsidiary of Inception Sciences, Inc.
Industry Biotechnology
Activity
What Changed Recently
Analyst View
Company Profile
CIK0001544227
ISINUS87978U2078
CUSIP87978U207
Phone415 798 8589
Address7000 Shoreline Court, Brisbane, CA, 94080, US
SEC EDGAR